66154-69-6 Usage
Uses
Used in Pharmaceutical Industry:
2-(Methylsulfonyl)isonicotinonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(Methylsulfonyl)isonicotinonitrile is utilized as a precursor in the production of agrochemicals. Its incorporation into these products can enhance their effectiveness in pest control and crop protection, contributing to increased agricultural productivity.
Used in Chemical Intermediates Production:
2-(Methylsulfonyl)isonicotinonitrile is employed as an intermediate in the synthesis of other chemicals. Its ability to react with various reagents makes it a valuable component in the creation of a wide range of chemical products, expanding its applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 66154-69-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,1,5 and 4 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 66154-69:
(7*6)+(6*6)+(5*1)+(4*5)+(3*4)+(2*6)+(1*9)=136
136 % 10 = 6
So 66154-69-6 is a valid CAS Registry Number.
66154-69-6Relevant academic research and scientific papers
Latli, Bachir,Hrapchak, Matt,Cheveliakov, Maxim,Reeves, Jonathan T.,Marsini, Maurice,Busacca, Carl A.,Senanayake, Chris H.
, p. 764 - 772 (2018)
1-(4-Fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (2-methanesulfonyl-pyridin-4-ylmethyl)-amide (1) and its analogs (2) and (3) are potent CCR1 antagonists intended for the treatment of rheumatoid arthritis. The detailed syntheses of these 3
AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
-
Page/Page column 169, (2010/04/27)
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
